# Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

> **NCT00460109** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 24 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** denileukin diftitox
- **BIOLOGICAL:** rituximab

## Key facts

- **NCT ID:** NCT00460109
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2010-10
- **Final completion:** 2011-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00460109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00460109, "Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00460109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*